Details

NameSymbolSector
SANDU PHARMACEUTICALS LTD.SANDUPHQPharmaceuticals
Open
46.94
High
46.95
Low
46.2
Close
46.28
Volume
997
Exchange
bse
Time
03-Oct-2025

Outlook

Score:  

1.5

Rating:  

RISKY

Candlestick Pattern

Candle pattern of Sandu Pharmaceuticals is  
Opening Marubozu
Estimated Stoploss of Sandu Pharmaceuticals is ₹  
46.95
Sandu Pharmaceuticals has a  
Bearishℹ
 pattern. 
Formation of  
Opening Marubozu
 candle pattern indicates Sandu Pharmaceuticals has chances of  
Continuationℹ
 of the current trend. 

Trend

Sandu Pharmaceuticals is in  
Sideways trendℹ
. 
Price of Sandu Pharmaceuticals is  
Downℹ
 by  

3.64

%. 
Target
Buy @ 

46.15

Sell @ 

50.91

Current @ 

46.28

Volume

The trade volumes of Sandu Pharmaceuticals have become  
Deficientℹ
The volume trend for Sandu Pharmaceuticals is  
Bearishℹ
, but the participants are  
Weak Sellersℹ
The trade volume of Sandu Pharmaceuticals is  

Down

 by  

50.99

% 

Valuation

The current market price of Sandu Pharmaceuticals is  
Undervaluedℹ

Financials

Balance
With total liablities and shareholder equity worth ₹ 55cr and total assets worth ₹ 55cr, the balance sheet of Sandu Pharmaceuticals is:  
Balancedℹ
. 
Cashflow
Sandu Pharmaceuticals has  
Poorℹ
 cash flow because it is  

₹ 0cr

. It is  
Downℹ
 by  

200

%. 

(*Mar 2025)

0% in operatingℹ
100% in investingℹ
0% in financingℹ
0% in otherℹ
Income
The income of Sandu Pharmaceuticals is  

₹ 16cr

 and  

Loss

 is :  

₹ 0cr

(*Jun 2025)

Sandu Pharmaceuticals Losses increased by:  

0

% and Income is Up by:  

14.29

% 

(*Jun 2025)

The income of Sandu Pharmaceuticals is  

₹ 14cr

 and  

Loss

 is :  

₹ 0cr

(*Mar 2025)

Sandu Pharmaceuticals Losses increased by:  

0

% and Income is Down by:  

22.22

% 

(*Mar 2025)

The income of Sandu Pharmaceuticals is  

₹ 18cr

 and  

Loss

 is :  

₹ 0cr

(*Dec 2024)

Sandu Pharmaceuticals Losses increased by:  

0

% and Income is Up by:  

5.88

% 

(*Dec 2024)

By using this site you agree to the use of cookies to deliver a better site experience.